# Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer

> **NCT02247037** · — · COMPLETED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 68 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **OTHER:** Chemotherapy

## Key facts

- **NCT ID:** NCT02247037
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2019-01-22
- **Final completion:** 2019-01-22
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2020-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02247037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02247037, "Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02247037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*